Want to see TSE:MBX full AI Analyst Report?
MBX Stock Chart & Stats
C$0.30
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.30
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.21 - C$0.33
Previous CloseN/A
Volume7.02K
Average Volume (3M)57.61K
Market Cap
C$42.63M
Enterprise ValueC$40.83
Total Cash (Recent Filing)C$7.16M
Total Debt (Recent Filing)C$6.72M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding137,501,160
10 Day Avg. Volume59,614
30 Day Avg. Volume57,610
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.33
Price to Sales (P/S)1.98
P/FCF Ratio-42.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.40Price Target Upside33.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)C$18.30M
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Broader Customer BaseThe return to double-digit growth and active customer diversification can rebuild the revenue base after prior client setbacks. Adding programs and customers may improve recurring demand and reduce dependence on a few large accounts over the next several quarters.
Improving Margins And Production EfficiencyHigher yields, automation and better fixed-cost absorption provide a durable path to stronger gross margins as volume recovers. These operational improvements can increase scalability and support progress toward breakeven without relying solely on price increases.
Manageable Leverage Supports Strategic FlexibilityModerate leverage limits balance-sheet pressure while the company rebuilds sales and funds production capacity. Although profitability is weak, the relatively low debt burden gives management more flexibility to invest in diagnostics growth and execute its Kinlytic program.
Bears Say
Persistent Losses And Negative Cash GenerationThe company is not currently self-funding: losses and negative operating cash flow reduce financial resilience and may require cash preservation or external funding. Sustained margin pressure would constrain investment in capacity and delay the path to durable breakeven.
China Business Remains Structurally Below Its Prior PeakThe prolonged China decline removes a meaningful historical revenue contributor and leaves recovery dependent on uncertain market conditions. Even management’s normalized target is far below the prior peak, limiting near-term operating leverage and geographic diversification.
Revenue Timing Depends On Clients And Product OrdersClient-controlled qualification and purchasing schedules can delay revenue recognition and make growth uneven. Limited VTM/DxTM orders add product-line risk, leaving results more dependent on a smaller set of programs and successful conversion of prospective customers.
Microbix Biosystms News
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.21 and its highest was C$0.33 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Microbix Biosystms J’s market cap is C$42.63M.
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is Dec 17, 2026 which is in 119 days.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on Aug 13, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 137,501,160 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Microbix Biosystms J
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
MBX Stock 12 Month Forecast
Average Price Target
C$0.40
▲(33.33% Upside)
Technical Analysis
BriaCell Therapeutics
―
Resverlogix
―
Devonian Health Group
―
Defence Therapeutics
―
Thiogenesis Therapeutics Corp
―